Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review.

ABSTRACT:

Background and objective

The prognostic value of age and other non-hematological factors in predicting outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) undergoing antileukemic therapy is not well understood. We performed a systematic review to determine the association between these factors and mortality and health-related quality of life or fatigue among these patients.

Methods

We searched Medline and Embase through October 2021 for studies in which researchers quantified the relationship between age, comorbidities, frailty, performance status, or functional status; and mortality and health-related quality of life or fatigue in older patients with AML receiving antileukemic therapy. We assessed the risk of bias of the included studies using the Q

SUBMITTER: Hao Q 

PROVIDER: S-EPMC9721486 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature